Abstract No. 567 Yttrium-90 radioembolization therapy for combined hepatocellular and cholangiocarcinoma

Abstract

To report outcomes of transarterial radioembolization (TARE) using glass microspheres for the treatment of mixed hepatocellular-cholangiocarcinoma (HCC-CC). Between 2013 and 2019, 10 consecutive patients with histologically confirmed HCC-CC received 1 or 2 TARE treatments of a targeted territory using glass microspheres. Baseline demographics in addition to tumor distribution, Child Pugh score, and BCLC were recorded. Tumor response was assessed according to modified RECIST criteria. Six-month mortality and adverse events were monitored for each patient. Adverse events were graded by standardized criteria using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Eight (80%) patients (4 males, 4 females) received a single TARE treatment and two (20%) patients underwent two. Tumor responses at 6 months were complete and partial in 80% and 20% patients respectively. No patients demonstrated tumor progression. No major toxicity was observed after 1st or 2nd treatment of RE. Two grade 2 adverse events were seen (Table 1). 6-month mortality was 10% (n = 1). While outcomes of combined HCC-CC are poor and optimal treatment remains undefined, TARE appears to represent a safe and promising locoregional treatment for disease control with an acceptable toxicity profile.Table 1Patient #Adverse Events after 1st Procedure (CTCAE Grade)Adverse Events after 2nd Procedure (CTCAE Grade)6 Month Mortality1 Year Mortality2 Year MortalityChild Pugh ScoreBCLCTumor LocationRECIST Rating1NoneNoneYYY6 (A)BRPartial2Abdominal Pain and Fatigue (2)NoneNNN5 (A)BLComplete3Fever (2)NoneNNN5 (A)ARComplete4NoneNoneNNN5 (A)ABiliary DuctComplete5NoneNoneNNN6 (A)ALComplete6NoneNoneNNN5 (A)ARComplete7NoneNoneNNN5 (A)ARPartial8NoneNoneNNN5 (A)ARComplete9NoneNoneNNN5 (A)ARComplete10NoneNoneNNN5 (A)ALComplete Open table in a new tab